cyclosporine A + methylprednisolone + mycophenolate mofetil

This is a combination immunosuppressive regimen consisting of three agents: - **Cyclosporine A** is a calcineurin inhibitor that suppresses T-cell activation by inhibiting the transcription of interleukin-2 and other cytokines, thereby reducing immune responses[6][9]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts primarily by modulating gene expression to suppress pro-inflammatory cytokines and immune cell activity. - **Mycophenolate mofetil** is an antimetabolite immunosuppressant that inhibits inosine monophosphate dehydrogenase, blocking de novo purine synthesis in lymphocytes, leading to reduced proliferation of T and B cells[2][7]. This triple-drug regimen is commonly used for the prevention of organ transplant rejection (renal, cardiac, hepatic) and for treatment or maintenance therapy in certain autoimmune diseases such as steroid-resistant nephrotic syndrome. The combination leverages different mechanisms to achieve synergistic immunosuppression while minimizing toxicity from any single agent[4][5][1].